58 related articles for article (PubMed ID: 12170424)
1. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.
Crassini K; Gibson J
Intern Med J; 2024 Jan; 54(1):16-25. PubMed ID: 38066723
[TBL] [Abstract][Full Text] [Related]
3. Changes in mortality associated with different hematologic malignancies during the pandemic in the United States.
Fedeli U; Barbiellini Amidei C; Han X; Jemal A
Int J Cancer; 2024 May; 154(10):1703-1708. PubMed ID: 38335457
[TBL] [Abstract][Full Text] [Related]
4. Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees.
Wiernik PH; Dutcher JP
J Investig Med; 2024 Jan; 72(1):26-31. PubMed ID: 37864488
[TBL] [Abstract][Full Text] [Related]
5. Precision pharmaceutical care in oncohematology.
Morillo-Verdugo R; Lizeaga-Cundin G
Farm Hosp; 2024; 48(3):91-92. PubMed ID: 38658254
[No Abstract] [Full Text] [Related]
6. [Translated article] Precision pharmaceutical care in oncohematology.
Morillo-Verdugo R; Lizeaga-Cundin G
Farm Hosp; 2024; 48(3):T91-T92. PubMed ID: 38705827
[No Abstract] [Full Text] [Related]
7. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.
Schmidt-Hieber M; Busse A; Reufi B; Knauf W; Thiel E; Blau IW
J Cancer Res Clin Oncol; 2009 Feb; 135(2):227-34. PubMed ID: 18719942
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine in the treatment of hematologic malignancies. Introduction.
Diehl V; Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
[No Abstract] [Full Text] [Related]
9. Hematologic malignancies: new developments and future treatments.
Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
[TBL] [Abstract][Full Text] [Related]
10. Phase I studies with bendamustine: an update.
Schrijvers D; Vermorken JB
Semin Oncol; 2002 Aug; 29(4 Suppl 13):15-8. PubMed ID: 12170427
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
12. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
